首頁 > 市場調查報告書 > 製藥

精神疾病

發作性睡病治療市場規模、佔有率和成長分析（按治療類型、疾病類型和地區分類）—產業預測（2026-2033 年）

市場調查報告書

商品編碼

1899392

發作性睡病治療市場規模、佔有率和成長分析（按治療類型、疾病類型和地區分類）—產業預測（2026-2033 年）

Narcolepsy Drugs Market Size, Share, and Growth Analysis, By Therapeutic Type (Sodium Oxybate, Central Nervous System Stimulants), By Disease Type (Daytime Extreme Sleepiness, Catalplexia), By Region -Industry Forecast 2026-2033

出版日期: 2025年12月23日 | 出版商:

SkyQuest | 英文 219 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

預計到 2024 年，嗜睡症治療市場規模將達到 40.5 億美元，到 2025 年將達到 44.3 億美元，到 2033 年將達到 91.7 億美元，在預測期（2026-2033 年）內複合年成長率為 9.5%。

由於人們對心理健康的認知不斷提高以及睡眠障礙盛行率的上升，嗜睡症治療市場正在經歷變革。嗜睡症診斷率的上升、對創新治療方法研發的投資以及對提高生活品質日益成長的需求，是推動市場擴張的關鍵因素。監管機構正在加快醫藥品認證過程，以滿足尚未滿足的醫療需求，這為製藥公司提供了巨大的成長機會。此外，藥物發現和研發技術的進步有望促進嗜睡症療法在全球的普及。然而，認知度低、潛在的副作用以及來自非藥物療法的競爭等挑戰可能會阻礙市場成長。平衡這些趨勢對於相關人員應對未來的趨勢和需求至關重要。

嗜睡症治療市場促進因素

人們對心理健康的日益關注顯著提升了對包括嗜睡症在內的各種疾病的理解和認知。隨著壓力和焦慮的加劇，應對這些挑戰也日益受到重視。針對心理健康問題的新措施和計畫將增強嗜睡症治療市場的未來潛力。這種對尋找有效治療方案的日益重視預計將推動對創新藥物的需求，最終強化市場格局，並提高嗜睡症患者的照護品質。

嗜睡症治療市場的限制

由於大眾對發作性睡病的症狀和影響了解有限，尤其是在發展中和低度開發地區，發作性睡病藥物市場面臨嚴峻挑戰。這種知識不足導致許多發作性睡病患者未能得到診斷和治療，對發作性睡病藥物的需求產生了負面影響。有針對性的宣傳活動和宣傳活動有助於提高公眾對該疾病及其治療方案的認知，從而可能緩解這一限制並擴大發作性睡病藥物市場。提高公眾意識將有助於早期診斷，改善患者的治療效果，最終推動市場成長。

嗜睡症治療市場趨勢

嗜睡症藥物市場正經歷著基於Orexin治療方法的顯著發展，這主要得益於此類療法有望更有效地解決疾病的根本原因，同時最大限度地減少副作用。隨著製藥公司加強對Orexin受體促效劑研發的投入，這些創新治療方法正日益受到醫療服務提供者和患者的關注。這一市場趨勢反映了人們為拓展治療選擇、提高患者生活品質所做的努力。隨著基於Orexin的治療方法逐漸成為傳統治療方法的可行替代方案，預計未來幾年嗜睡症藥物市場將迎來顯著成長和發展。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲（MEA）
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭格局

前五大公司對比
主要企業的市場定位（2025 年）
主要市場參與者所採取的策略
近期市集活動
主要企業市佔率（2025 年）

主要企業簡介

Jazz Pharmaceuticals plc
Teva Pharmaceutical Industries Ltd.
Bioprojet Pharma SARL
Novartis International AG
Takeda Pharmaceutical Company
Avadel Pharmaceuticals
Mylan NV（now part of Viatris）
Aurobindo Pharma
Glenmark Pharmaceuticals
Lupin Pharmaceuticals
Otsuka Pharmaceutical
Biogen
Theravance Biopharma
Ligand Pharmaceuticals
Flamel Technologies（now Avadel Pharmaceuticals）
Biocodex
Sun Pharmaceutical Industries
Cipla Limited
Dr. Reddy's Laboratories
Pfizer Inc.

簡介目錄

Product Code: SQMIG35I2087

Narcolepsy Drugs Market size was valued at USD 4.05 Billion in 2024 and is poised to grow from USD 4.43 Billion in 2025 to USD 9.17 Billion by 2033, growing at a CAGR of 9.5% during the forecast period (2026-2033).

The narcolepsy drugs market is poised for transformation driven by heightened mental health awareness and the rising incidence of sleep disorders. An increasing number of narcolepsy diagnoses, investments in innovative treatment development, and a growing demand for lifestyle enhancements are key drivers for market expansion. Regulatory bodies are expediting drug approval processes to address unmet medical needs, offering significant opportunities for pharmaceutical companies. In addition, advancements in drug discovery and development technologies are expected to enhance global adoption of narcolepsy medications. However, challenges such as limited awareness, potential side effects, and competition from non-pharmacological treatments may impede growth prospects in the market. Balancing these dynamics will be crucial for stakeholders in navigating future trends and demands.

Top-down and bottom-up approaches were used to estimate and validate the size of the Narcolepsy Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Narcolepsy Drugs Market Segments Analysis

Global Narcolepsy Drugs Market is segmented by Disease Type, Therapeutics Type, and region. Based on Disease Type, the market is segmented into Daytime Extreme Sleepiness, Cataplexia, and Other Disease Type. Based on Therapeutics Type, the market is segmented into Central Nervous System Stimulants, Tricyclic Antidepressants, Sodium Oxybate, Selective Serotonin Reuptake Inhibitor, and Other Therapeutic Type. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Driver of the Narcolepsy Drugs Market

The growing awareness of mental health has significantly contributed to the understanding of various disorders, including narcolepsy, which has become increasingly prevalent. As stress and anxiety rates escalate, so does the focus on addressing these challenges. New initiatives and programs aimed at tackling mental health issues will likely enhance the future potential of the narcolepsy drugs market. This heightened emphasis on finding effective solutions for patients suffering from narcolepsy is expected to drive demand for innovative medications, ultimately strengthening the market landscape and improving the quality of care for those affected by this condition.

Restraints in the Narcolepsy Drugs Market

The narcolepsy drugs market faces significant challenges due to limited awareness of the symptoms and effects of narcolepsy across various regions, particularly in developing and underdeveloped areas. This lack of knowledge results in many individuals with narcolepsy remaining undiagnosed and untreated, which adversely impacts the demand for narcolepsy medications. By implementing targeted awareness programs and campaigns, it is possible to educate the public about the condition and its treatment options, thereby helping to alleviate this constraint and potentially enhancing the market for narcolepsy drugs. Increased awareness can lead to earlier diagnosis and improved patient outcomes, ultimately boosting market growth.

Market Trends of the Narcolepsy Drugs Market

The narcolepsy drugs market is witnessing a significant shift towards the development of orexin-based therapies, driven by their potential to more effectively address the disorder's underlying causes with fewer adverse effects. As pharmaceutical companies increasingly invest in research and development of orexin receptor agonists, these innovative treatments are poised to gain traction among both healthcare providers and patients. This market trend reflects a broader commitment to enhancing treatment options and improving patient quality of life. As orexin-based therapies emerge as a viable alternative to traditional treatments, the narcolepsy drugs market is likely to experience substantial growth and evolution in the coming years.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Key Success Factor
Degree of Competition
Top Investment Pockets
Ecosystem of the Market
Regulatory Analysis
Case Study Analysis
Clinical Trials

Narcolepsy Drugs Market, By Disease Type

Market Overview
Daytime Extreme Sleepiness
Cataplexia
Other Disease Type

Narcolepsy Drugs Market, By Therapeutics Type

Market Overview
Central Nervous System Stimulants
Tricyclic Antidepressants
Sodium Oxybate
Selective Serotonin Reuptake Inhibitor
Other Therapeutic Type

Narcolepsy Drugs Market Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2025

Key Company Profiles

Jazz Pharmaceuticals plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical Industries Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bioprojet Pharma SARL
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis International AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takeda Pharmaceutical Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Avadel Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Mylan N.V. (now part of Viatris)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Aurobindo Pharma
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Glenmark Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Lupin Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Otsuka Pharmaceutical
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biogen
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Theravance Biopharma
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ligand Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Flamel Technologies (now Avadel Pharmaceuticals)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biocodex
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sun Pharmaceutical Industries
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cipla Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Dr. Reddy's Laboratories
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments